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AbstrAct
The macrophage activation syndrome (MAS) and the sepsis are both a condition of hyperinflammation. The differential diagnosis can be difficult. 
The two pathologies can succeed with each other. The purpose of this literature review is to illustrate these diagnostic and therapeutic difficulties 
through a reported case of a macrophage activation syndrome secondary to infection (MASI). It was a 42-year-old diabetic man, hospitalized 
for an acute myositis due to an infection of Staphylococcus aureus. These germs caused a septic shock requiring antibiotic therapy. After an 
initial clinical improvement, the diagnosis of MASI post-Staphylococcus aureus was retained with a persistence of the inflammatory syndrome 
and appearance of fever with splenomegaly associated with hepatic cytolysis a 30% decrease in prothrombin time, a mild regenerative anemia 
without hemophagocytosis. An inflammatory syndrome may have several completely opposite etiologies and pathophysiology. Our case 
fulfilled both of the criteria of sepsis and MAS. Several signs were common for the two pathologies, but a detailed analysis of the clinical and 
biological elements lead to the diagnostic orientation. 
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IntroductIon
Macrophagic activation syndrome (MAS) is a condition of 
pathological hyper-inflammation leading to benign hystio-
lymphocytosis hyperprolifération.[1] Sepsis is defined as an 
inappropriate systemic response due to infection with multivisceral 
organ failure.[2] It can be difficult to distinguish a SAM and sepsis, 
as the boundary between inflammation and infection can be 
blurred. In both cases, the prognosis may be affected; they are life-
threatening dydisease, especially since the treatment is practically 
the opposite between these two diseases. The difficulty is even 
ugreater when it is knew that MAS can be secondary to infectious 
reactive sepsis (MASI), and a MAS can become complicated by 
sepsis. Saim is to illustrate these diagnostic and therapeutic 
difficulties through a case report.
Observation
We reported a case of a 42- year- old man who presented with a post-
traumatic muscle pain of the left thigh. During his hospitalization, 
we discovered a type 2 diabetes complicated by ketoacidosis. The 
patient had no specific history other than repeated furunculosis. 
Initial biological check-up showed inflammatory syndrome with a 
high CRP level at 109 mg /L, hyperleukocytosis with a large amount 
of polymorphonuclear cells (18 G/L and 14 G/L). The platelet count 
was 62G /L. The creatinine and serum electrolytes were normal. 
The soft tissue ultrasound revealed a musculo-aponevrotic 
disinsertion of the left vastus lateralis muscle in his proximal 
insertion. Thus, the patient received ketoprofen as treatment with 
icing and rest, as well as insulin therapy and hyperhydration in 
relation to his diabetes.
After a marked initial clinical improvement, the patient 
had a fever at 39.5°C on the four’s day of hospitalization with 
re-emergence of myositis sign. On day 5, his condition had rapidly 
deteriorated following a septic shock. The computed tomography 
scan of the soft tissue objectified multiple micro-abscesses in the 
pectineus, left external obturator, and iliopsoas muscles. In view of 
this infective myositis, he received Ceftriaxone 2g/d, Ciprofloxacin 
800 mg/d and Gentamycin 3 mg/kg/d targeting Staphylococcus 
aureus identified in the blood culture. The progression was marked 
at day 10 of hospitalization and Day 5 of antibiotic therapy by the 
lifting of the shock state and the disappearance of the signs of 
myositis. On the other hand, the fever persisted in a plateau at 40°C, 
accompanied by splenomegaly. 
Biologically, the blood culture control and the urinalysis 
were negative, but there was an appearance of normocytic 
and normochromic anemia poorly regenerative at 8.5 g/dL, 
hyperleukocytosis at 25 G/L (85% of polymorphonuclear cells), 
thrombocytopenia at 98 G/L. CRP remained elevated at 139 mg/L.
This picture of a persistent clinico-biological inflammatory 
syndrome with bicytopenia prompted us to carry out a medullo-
gram showing a bone marrow of normal richness without 
hemophagocytosis. There was markedly raised ferritinemia at 
100,000 IU/mL, hypertriglyceridemia at 4mmol/L (N < 1.7 mmol/L), 
elevated transaminases (AST at 2xN, ALT at 4xN), anicteric cholestasis 
with total bilirubinemia  at 24µmol/l (n < 17.1 µmol/L), Gamma-GT 
at 105 IU/L (N = 15 to 55 IU/L), normal alkaline phosphatases 400 
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IU /l (N = 30 to 100 IU/L), with a 30% decrease in prothrombin time. 
Doppler echocardiography eliminated endocarditis. Abdominal-
pelvic ultrasound confirmed splenomegaly but did not show any 
other abnormalities. 
We have mentioned the diagnosis of macrophage activation 
syndrome secondary to Staphylococcus aureus infection in front 
of this intense and persistent clinico-biological inflammatory 
syndrome with cytopenia. After 3 days of systemic corticosteroid 
(methylprednisolone) therapy with 120 mg/d, followed by 
prednisone per os at 1 mg/kg/d, fever and biological inflammatory 
syndrome disappeared in 3 days. The patient came out asymptomatic 
one week after corticosteroid therapy.
dIscussIon
An intense inflammatory syndrome may have multiple aetiologies 
and pathophysiology completely opposite. This is the case for our 
patient in whom sepsis, MASI, and MAS were triggered by the 
same causative agent: Staphylococcus aureus. Moreover, there is no 
defined chronology or established continuity of events between 
these three pathological entities, which makes diagnosis very 
difficult. 
Sepsis is a life-threatening organ dysfunction caused by an 
inappropriate host response to infection. The diagnosis is made 
in front of a sequential organ failure assessment (SOFA) score of 
> 2.[2] This score has been filled-in our case (hyperbilirubinemia, 
thrombocytopenia, and cardiovascular collapse). This is a diagnostic 
and therapeutic emergency. Any acute inflammatory syndrome 
should be investigated, and its etiological treatment initiated 
promptly.  
The MAS or Hemophagocytic lymphohistiocytosis (HLH) is a 
benign proliferation of lympho-hystiocytosis cells, resulting from a 
state of hyper-inflammation, secondary to an abnormality of CD8+ 
T-cell (LT CD8).[1,3] This is due to the inability of the LT to remove a given 
antigen, including infectious agents. This permanent stimulation 
of LT will lead to hyperproliferation with hyper inflammation state 
(phagocytosis, hyperproduction of pro-inflammatory cytokine). 
There are two types of MAS: primary MAS and secondary or acquired 
MAS.[4] Reactive MAS may be secondary to several pathologies: 
hemopathy, neoplasia, and infectious disease. To diagnose the MAS, 
several diagnostic criteria were established, including the HLH 2004 
criteria (HemophagocyticLymphoHistiocytosis), including clinical, 
biological, and histological parameters.[5] MAS diagnosis is retained 
when the score is > 5. Our patient met these diagnostic criteria 
with a score of 5, which allowed us to diagnose MAS secondary to 
Staphylococcus aureus septicemia.
The MASI is a bridge between the two diseases. This is actually 
a MAS that is reactive to an infection. Clinically there is no obvious 
difference between the manifestations of MAS and MASI outside 
the fact that MASI occurs in adults rather than in primitive MAS. 
And also, the presence of a severe infection that should be sought 
before all MAS and during its evolution. The main agents involved 
are viruses, which account for almost half of the aetiologies of 
the MASI, followed by bacteria in about 16% of cases, and mainly 
common germs (13.7%).[3] Staphylococcus aureus was twice the 
infectious agent found by Bourkisand al during its study of 11 cases 
of MASI.[6] The diagnostic criterion remains that of HLH 2004.
There are no pathognomonic signs for each of these three 
pathological entities, but the diagnosis is made mainly on a fine 
analysis of the clinical-biological elements. Indeed, some diagnostic 
elements may be useful to evoke MAS. Ferritinemia, a marker of 
macrophage activity, was higher during MAS than in a sepsis. In a 
review of the literature by Machowiz and al., the mean ferritinemia 
value was 3171 ng/mL with a maximum of 210170 ng/mL compared 
with a median value of 590 ng/mL in the sepsis.[7] Our patient had 
severe hyperferritinemia at 100,000 IU/L (Table 1).  
CPR is a protein of IL-6-mediated inflammation. A CPR value of 
> 100 mg/L is typically considered secondary to bacterial infection. 
This rise in CPR is less marked in the MAS.[8] However, failure to 
degrade CRP after proper antibiotic therapy led us to look for another 
non-infectious cause of the manifest inflammatory syndrome. 
Cytopenia was more frequent and deeper in the MAS than in the 
sepsis. It is secondary to the production of Interferon-gamma and 
TNF-alfa, which inhibit hematopoiesis, cytopenia being aggravated 
by the hemophagocytosis. Pancytopenia in MAS is mostly due to 
high levels of TNF-alfa and IFN-gamma (ineffective erythropoiesis), 
with hemophagocytosis playing a minor role. Kaihlembergand al 
found median hemoglobin of 7.8-8.5 g/dl in patients with MAS.[8] For 
sepsis, the median is 10.4 g/dl of hemoglobin.[9] For platelet count, 
Liand et al. reported an average of 27-53 G/L in patients with MAS, 
and 93% of patients had platelet counts <100G/L.[10] In the course 
of sepsis, the presence of thrombocytopenia is mostly secondary 
to DIC (disseminated intravascular coagulation) or evolution to a 
state of septic shock, the value usually found as below <150G/L. 
The frequency of thrombocytopenia in severe sepsis was 14.5% 
in a prospective registry of over 1200 patients and platelet count 
exceeds 100 × 109/L in the majority of patients, even with severe 
sepsis and septic shock.[11] This bicytopenia was present in our 
patient, which didn’t add up to the diagnosis.  
The level of trygliceridemia also has a diagnostic orientation 
value. Hypertriglyceridemia in SAM is due to inhibition of lipoprease 
by TNF alfa. Triglycerides are higher in sepsis than in MAS with values 
of 440 mg/dL versus 180 mg/dl in serial studies.[12,13] 
The same applies to the value of fibrinogenemia, the fibrinogen 
being cleaved by plasmin produced by activated macrophages. This 
Table 1: commonalities between MAS and sepsis reported according to the HLH 2004 diagnostic criteria for the diagnosis of MAS
HLH criteria MAS Sepsis Case
Fever 100% 90–100% Present
Hepatosplenomegaly 70–100% 79% Present
Cytopenia :
Anemia
Thrombopenia
90–100%
86%–100%
51,6%
14,5%– 26%
Hb 8,5 G/dL
Platelets 98G/L
Hypertriglyceridemia
Hypofibrinogénemia
60–70%
65–80%
81%
7%–76%
4mmol/L
Not dosed
Lowactivity NK* 36% 96% Not dosed
Ferritinémia>50µg/L 55–70% 33,3% 100.000 UI/L
Soluble Il 2 receptor * 93% Not dosed
Hémophagocytosis 66,6%–100% 83% Not dosed
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value is lower in MAS; the median value is  105ng/dL. In contrast, in 
the sepsis, except in the case of DIC, fibrinogenemia would readily 
exceed 500 ng/dL.[14]
Finally, the presence of hemophagocytosis is not a discriminatory 
element. The sensitivity of this sign is 75–100% in MAS’s series. 
However, hemophagocytosis can occur in many other conditions 
besides MAS, for example, after a blood transfusion or influenza. 
Hemophagocytosis reported to be present in 64% of patients 
hospitalized for resuscitation and thrombocytopenia[15] and in 80% 
of patients who died as a result of sepsis.[16,17] 
Table 1 compares the frequency of the clinical and biological 
components found in the MAS and the severe sepsis, and also 
what was found in our patient. The strong points that led to the 
diagnosis in our patient were the identification of Staphylococcus 
aureus as the causal agent of the entire event. It was responsible 
for septicemia following myositis. The well-conducted antibiotic 
therapy eradicated the infection, but the secondary intensification 
of the inflammation corresponding with the diagnostic criteria 
of the HLH 2004 allowed us to make the diagnosis of MAS. The 
diagnosis was supported by the clinical-biological improvement of 
the patient on corticosteroid therapy, which could have aggravated 
the disease in the event of infection.
conclusIon
A hyper-inflamed state has multiple etiologies, sepsis and MAS are 
part of it. These two pathologies can succeed each other, and one 
can be the cause or the consequence of the other. The presence of 
MAS should be investigated for the absence of improvement in an 
infectious state despite adequate antibiotic therapy. In the absence 
of pathognomonic signs for each disease, fine analysis of clinical-
biological components such as ferritinemia, CRP, trygliceridemia, 
and cytopenias are valuable aids in diagnostic guidance. 
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